Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen

This study has been completed.
Sponsor:
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00316225
First received: April 18, 2006
Last updated: June 10, 2010
Last verified: June 2010
Results First Received: March 10, 2010  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Non-small Cell Lung Cancer
Mesothelioma
Lung Neoplasms
Intervention: Drug: pemetrexed

  Participant Flow


  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Pemetrexed Pemetrexed 500 mg/m2 intravenous (IV) every 21 days for 6 cycles

Baseline Measures
   Pemetrexed 
Overall Participants Analyzed 
[Units: Participants]
 31 
Age 
[Units: Years]
Median (Full Range)
 62.7 
 (35.7 to 77.5) 
Gender 
[Units: Participants]
 
Female   4 
Male   27 
Race/Ethnicity, Customized 
[Units: Participants]
 
Caucasian   30 
Hispanic   1 
Region of Enrollment 
[Units: Participants]
 
Spain   12 
Denmark   6 
Germany   13 
Diagnosis [1] 
[Units: Participants]
 
Non-Small Cell Lung Cancer (NSCLC)   23 
Mesothelioma   8 
[1] Diagnosis of Non-Small Cell Lung Cancer (NSCLC) and mesothelioma were determined by each individual investigator.
Disease Stage [1] 
[Units: Participants]
 
Stage III (locally advanced disease)   12 
Stage IV (metastatic disease)   18 
Unknown   1 
[1] Stage means how big the tumor is and how far it has spread. Stages range from 0 (not spread) to IV (spread throughout the body).
Eastern Cooperative Oncology Group (ECOG) Performance Status [1] 
[Units: Participants]
 
0 - Fully Active   14 
1 - Ambulatory, Restricted Strenuous Activity   17 
[1] Classifies patients according to their functional impairment. Scores range from 0 (Fully Active) to 5 (Death).
Fluid Severity [1] 
[Units: Participants]
 
Mild   15 
Moderate   14 
Severe   2 
[1]

Mild = (1) pleural effusion detectable on radiological imaging, but less than moderate; (2) ascites detectable only by radiological imaging. Moderate = (1) pleural effusion less than 1/3 of the way up the thorax on 1 side on imaging and obscuring the entire hemidiaphragm on that side; (2) ascites detectable on physical exam (that is, fluid wave is palpable). Severe = (1) pleural effusion more than 1/3 of the way up the thorax on imaging; (2) ascites visibly detectable.

For Moderate Fluid Severity, there were 13 patients with pleural effusion and 1 patient with ascites.

Primary Basis for Diagnosis 
[Units: Participants]
 
Cytological   6 
Histopathological   25 
Type of Third-Space Fluid 
[Units: Participants]
 
Pleural Effusion   30 
Ascites   1 
Body Surface Area 
[Units: Meters squared (m^2)]
Median (Full Range)
 1.8 
 (1.4 to 2.3) 
Height 
[Units: Centimeters (cm)]
Median (Full Range)
 171.0 
 (147.0 to 189.0) 
Weight 
[Units: Kilograms (kg)]
Median (Full Range)
 68.0 
 (47.9 to 100.0) 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Overview of Adverse Events   [ Time Frame: baseline, up to 18 weeks ]

2.  Secondary:   Number of Participants With Common Toxicity Criteria - National Cancer Institute Grade 3 and Grade 4 Toxicities   [ Time Frame: baseline, up to 18 weeks ]

3.  Secondary:   Pemetrexed Population Pharmacokinetics (PK): Clearance   [ Time Frame: Cycle 1 and Cycle 2: before the end of infusion (approximately 9.5 minutes), 2 hours, 9-10 hours, 24-48 hours, 480-528 hours (20 to 22 days) after start of pemetrexed infusion ]

4.  Secondary:   Pemetrexed Population Pharmacokinetics: Volume of Distribution   [ Time Frame: Cycle 1 and Cycle 2: before the end of infusion (approximately 9.5 minutes), 2 hours, 9-10 hours, 24-48 hours, 480-528 hours (20 to 22 days) after start of pemetrexed infusion ]

5.  Secondary:   Discontinuations Due to Adverse Events   [ Time Frame: baseline, up to 18 weeks ]

6.  Other Pre-specified:   Overall Tumor Response   [ Time Frame: baseline, up to 18 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information